Independent · non-commercial · publishes on a quarterly cycle|Current cycle 2026 Q3
Compound Evidence InstituteEvidence synthesis · established 2023Graded assessments of compounds, trials, methods and supply
Document set current to 30 July 2026
Public comment period · §2

Draft synthesis: Discontinued development programmes as… — submissions

The 3 submissions received, published in full with declared interests and secretariat responses.

Document identifier
CEI-CP-113/2
Series
Public comment period
Version
1.0
Published
01 Mar 2026
Last reviewed
01 Mar 2026
Next review
01 Mar 2027
Identifier
10.71829/cei.cp.113
Certainty
Not rated
Cycle
2026 Q1
Window
10 Jan 2026 – 09 Feb 2026
Status
Closed
Submissions
3

§2Submissions and responses

3 submissions were received. Each is published in full below with its declared interest, the secretariat response and the disposition. The Institute publishes submissions it did not accept in the same form as those it did.

Dr Delphine Trelawney, MD, PhD Academic clinical pharmacology unit · submitting on clinical pharmacology
DRAFT-DISCONTINUED/001 received 25 Jan 2026

Doses differing several-fold are pooled without examining dose-response

The draft review of What can be concluded from a development programme that was discontinued, and how should the Institute record it? was read against its registered protocol.

Contributing trials administer doses that differ by a factor of several. The draft pools them and reports one estimate. The respondent states that where a dose-response relationship exists the pooled figure corresponds to no dose that anyone receives.

The respondent proposes that estimates be reported by dose and that dose-response be examined where the data allow.

Declared interest. Has received travel support to attend a scientific meeting from a manufacturer of a compound named in the draft.
Secretariat responseAccepted18 Feb 2026

The secretariat accepts this submission. A pooled estimate across doses is an estimate for an average dose that no protocol specifies.

Estimates are now reported by dose group, a dose-response examination is reported where three or more dose levels contribute, and the pooled across-dose estimate is removed rather than retained alongside.

Dr Kolawole Isaksen-Balogun, PhD (Biostatistics) Independent evidence-synthesis consultancy · submitting on biostatistics
DRAFT-DISCONTINUED/002 received 27 Jan 2026

A funnel plot is presented for a set too small to interpret it

This submission addresses the draft synthesis on What can be concluded from a development programme that was discontinued, and how should the Institute record it? from the standpoint of a reader who will use the summary and not the appendices.

The draft includes a funnel plot for an outcome contributed by fewer than ten studies. The respondent states that asymmetry cannot be assessed reliably at that number and that presenting the plot invites a conclusion the data cannot support.

The respondent proposes that the plot be removed and replaced with a statement that publication bias could not be assessed.

Declared interest. Is a member of the Institute's external reviewer register but did not review the document under consultation.
Secretariat responseAccepted26 Feb 2026

The secretariat accepts this submission. Presenting an uninterpretable graphic is not a neutral act.

The funnel plot is removed for every outcome contributed by fewer than ten studies, and replaced by a statement that small-study effects could not be assessed at that number, together with the count of registered trials identified without posted results.

Dr Leonhard Quenneville, MD, PhD Metabolic medicine service, tertiary centre · submitting on clinical pharmacology
DRAFT-DISCONTINUED/003 received 07 Feb 2026

The comparator was given at a dose below the one in general use

Having read the draft synthesis on What can be concluded from a development programme that was discontinued, and how should the Institute record it?, the respondent puts one point to the committee.

Two contributing trials compare the intervention against an active comparator titrated to a dose lower than that reached in ordinary practice. Pooling them with trials using a full comparator dose produces an estimate that flatters the intervention.

The respondent proposes that comparator dose be tabulated in the included-studies table and that a sensitivity analysis restricted to full-dose comparators be reported.

Declared interest. Has previously served as an investigator on a trial included in the evidence base under consultation. Received no personal payment; institutional payment was made to the trial site.
Secretariat responseAccepted17 Feb 2026

The secretariat accepts this submission. Comparator dose is a condition of an effect estimate and was not being recorded.

Comparator dose is now a column in the included-studies table, and a sensitivity analysis restricted to comparators at the dose in general use is reported wherever the trials permit it.

References cited on this page

References are numbered in order of first citation in this document. Each superscript in the text links to its entry below.

  1. International Organization for Standardization. ISO/IEC 17025:2017 General Requirements for the Competence of Testing and Calibration Laboratories. ISO/IEC Standard 2017;3rd edition. identifier not held by the Institute

Identifiers are reproduced only where the Institute holds them. Where a digital object identifier or PubMed identifier is not shown, the Institute has recorded the journal and year and has not constructed an identifier.

Nothing published by the Institute is medical advice, a diagnosis, a prescription, a treatment recommendation or a purchasing recommendation. Compounds supplied for research use are not approved for human or veterinary use in any jurisdiction, and a favourable analytical assessment of a supplier is not a statement that any product is safe or effective. The Institute publishes certainty ratings and never recommendations. No telephone number, messaging handle or ordering channel appears anywhere on this site.